These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 29477208)

  • 41. Emerging clinical setting of direct oral anticoagulants: atherothrombotic events prevention.
    Di Fusco SA; Lucà F; Gulizia MM; Gabrielli D; Colivicchi F
    J Cardiovasc Med (Hagerstown); 2020 Jan; 21(1):1-5. PubMed ID: 31688432
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combining Intravenous Thrombolysis and Antithrombotic Agents in Stroke: An Update.
    Derex L; Paris C; Nighoghossian N
    J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29331961
    [No Abstract]   [Full Text] [Related]  

  • 43. Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.
    Ajmal M; Friedman J; Sipra QUAR; Lassar T
    Cardiovasc Ther; 2021; 2021():8886210. PubMed ID: 33505518
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Delayed-onset heparin-induced thrombocytopenia without thrombosis in a patient receiving postoperative thromboprophylaxis with rivaroxaban.
    Tardy-Poncet B; Piot M; Montmartin A; Burdier A; Chalayer E; Tardy B
    Thromb Haemost; 2015 Aug; 114(3):652-4. PubMed ID: 26062524
    [No Abstract]   [Full Text] [Related]  

  • 45. Indirect antiplatelet effects of rivaroxaban in a patient with intracranial hemorrhage: An underappreciated coagulopathy of factor Xa inhibitors?
    Gilbert BW; Tabaka CA
    Am J Emerg Med; 2022 Jan; 51():426.e5-426.e7. PubMed ID: 34244010
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
    Tangelder MJ; Nwachuku CE; Jaff M; Baumgartner I; Duggal A; Adams G; Ansel G; Grosso M; Mercuri M; Shi M; Minar E; Moll FL
    J Endovasc Ther; 2015 Apr; 22(2):261-8. PubMed ID: 25809373
    [TBL] [Abstract][Full Text] [Related]  

  • 47. VOYAGER PAD contributes to medical therapy for peripheral artery disease.
    Farber A
    J Vasc Surg; 2020 Dec; 72(6):1843-1844. PubMed ID: 33222822
    [No Abstract]   [Full Text] [Related]  

  • 48. Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients.
    Mackman N; Spronk HMH; Stouffer GA; Ten Cate H
    Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):726-732. PubMed ID: 29449336
    [No Abstract]   [Full Text] [Related]  

  • 49. Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios.
    McClure GR; Kaplovitch E; Narula S; Bhagirath VC; Anand SS
    Curr Cardiol Rep; 2019 Aug; 21(10):115. PubMed ID: 31471666
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bilateral adrenal gland hemorrhage in a patient treated with rivaroxaban.
    Comuth W; Christiansen JJ; Bloch-Münster AM; Husted S
    Blood Coagul Fibrinolysis; 2017 Jan; 28(1):102-104. PubMed ID: 26919451
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rivaroxaban for post-discharge thromboprophylaxis: the MARINER trial.
    Ramacciotti E; Fareed J
    Int Angiol; 2018 Dec; 37(6):427-430. PubMed ID: 30558402
    [No Abstract]   [Full Text] [Related]  

  • 52. Safe intravenous thrombolysis in acute stroke despite treatment with rivaroxaban.
    Bornkamm K; Harloff A
    J Clin Neurosci; 2014 Nov; 21(11):2012-3. PubMed ID: 24938385
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation.
    Rivera-Caravaca JM; Camelo-Castillo A; Ramírez-Macías I; Gil-Pérez P; López-García C; Esteve-Pastor MA; Orenes-Piñero E; Tello-Montoliu A; Marín F
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281167
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pulmonary Venous Thromboembolism in an Acutely Ill Medical Patient Receiving Rivaroxaban.
    Saleem A
    J Coll Physicians Surg Pak; 2017 Sep; 27(9):S129-S130. PubMed ID: 28969751
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hemorrhage Risk Profiles among Different Antithrombotic Regimens: Evidence from a Real-World Analysis of Postmarketing Surveillance Data.
    Sun X; Ze B; Zhang LJ; BaiMa YZ; Zuo W; Zhao B; GeSang LB
    Cardiovasc Drugs Ther; 2022 Feb; 36(1):103-112. PubMed ID: 33226545
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of DOACs in patients with peripheral arterial disease: A systematic review and meta-analysis.
    Zhang YS; Chen JH; Mei T; Li S; Lu YM
    Vascular; 2021 Dec; 29(6):846-855. PubMed ID: 33504278
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience.
    Arachchillage D; Reynolds R; Devey T; Maclean R; Kitchen S; van Veen JJ
    Thromb Res; 2016 Nov; 147():32-35. PubMed ID: 27669125
    [No Abstract]   [Full Text] [Related]  

  • 59. Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome.
    Prescrire Int; 2014 Oct; 23(153):229-32. PubMed ID: 25964962
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial.
    Nicholls SJ; Nelson AJ
    Am J Cardiovasc Drugs; 2019 Aug; 19(4):343-348. PubMed ID: 30680652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.